This company listing is no longer active
0PJ Stock Overview
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Allena Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.01 |
| 52 Week High | US$0.51 |
| 52 Week Low | US$0.002 |
| Beta | 1.53 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -97.14% |
| 3 Year Change | -99.58% |
| 5 Year Change | n/a |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0PJ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -2.0% |
| 1Y | -97.1% | -21.1% | -0.3% |
Return vs Industry: 0PJ underperformed the German Biotechs industry which returned 9.6% over the past year.
Return vs Market: 0PJ underperformed the German Market which returned -14% over the past year.
Price Volatility
| 0PJ volatility | |
|---|---|
| 0PJ Average Weekly Movement | 197.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0PJ's share price has been volatile over the past 3 months.
Volatility Over Time: 0PJ's weekly volatility has increased from 120% to 197% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 12 | n/a | www.allenapharma.com |
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Allena Pharmaceuticals, Inc. Fundamentals Summary
| 0PJ fundamental statistics | |
|---|---|
| Market cap | €1.55m |
| Earnings (TTM) | -€40.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs 0PJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0PJ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.30m |
| Earnings | -US$43.30m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 131.1% |
How did 0PJ perform over the long term?
See historical performance and comparison